BAFNAPHNSEBafna Pharmaceuticals LimitedLowNeutral
Announced Fri, 27 Mar · 13:22 IST

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on March 27, 2026, in which the Board of Directors has inter-alia considered and approved: (i). The appointment of M/s. K. S. Rao & Co., Chartered Accountants, Chennai as the Internal Auditor of the Company for the Financial Year 2026-2027; (ii). The appointment of M/s. N. Sivashankaran & Co., Cost Accountants, Chennai as the Cost Auditor of the Company for the Financial Year 2026-2027

Management Changes View source PDF

BAFNAPH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.6%1-day move
₹116.99
prior close
₹123.60
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.0-2.0-2.1-3.6-2.6-2.6-5.3-2.4+16.4+13.9+16.5+11.0+74.7
Up moveDown movePending
AI summary

Bafna Pharmaceuticals held a board meeting on March 27, 2026 (from 12:30 PM to 1:00 PM), where the Board approved two key appointments for FY 2026-2027. M/s. K. S. Rao & Co., Chartered Accountants (Chennai), a firm with over 4 decades of experience, was appointed as the Internal Auditor for a one-year term from April 1, 2026 to March 31, 2027. M/s. N. Sivashankaran & Co., Cost Accountants (Chennai), a well-established cost accounting firm, was appointed as the Cost Auditor for the same one-year period. Both appointments are routine regulatory compliance requirements under the Companies Act.

Likely market impact

This is a routine annual appointment of statutory auditors with no material impact on shareholders or stock price. It reflects standard corporate governance compliance and does not indicate any concerns about financial reporting.